As pointed out above, the loss of LAMP‐1 immunostaining in FTLD as a whole, compared to AD and controls, appeared to be driven in part by loss of LAMP‐1 from patients with SD and FTLD‐type C pathology. The gene discussed is LAMP1; the disease is Salla disease.